Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP)

Earlier this month, CRISPR Therapeutics announced positive Phase 1 data for its investigational in vivo CRISPR/Cas9 therapy CTX310, which showed substantial and durable reductions in key lipid levels ...
techtimes

CRISPR Technology Explained: The Science of Gene Editing, DNA Modification, and Genetic Engineering Ethics Uncovered

Discover how scientists are harnessing the power of CRISPR to precisely edit DNA, revolutionizing medicine and ethics as they rewrite the very code of life. Pixabay, PublicDomainPictures CRISPR ...